From first market assessment to scaled commercial operations, every service is delivered with operator-level depth — not just advisory slides.
Before a dollar is spent on launch, you need to know exactly where the opportunity lives. We build the evidence base that de-risks every downstream decision.
A complete go-to-market architecture built for North American adoption — pricing, channels, distribution, and launch sequencing that reflect how devices actually get bought.
Dual-market expertise is Apex's core differentiator — commercial strategy and market access for both countries, with regulatory specialists engaged through Apex's expert network where needed.
Software-driven and AI-enabled devices face a different commercialization playbook — evolving regulation, novel reimbursement, and buyers who evaluate technology, not just clinical outcomes.
Two decades of relationships across key specialties in the US and Canada. We identify, engage, and cultivate the clinical voices that determine whether your technology gets adopted.
Growing engagement from PE/VC firms and family offices seeking an operator's eye on medtech deals — plus sell-side and partnering support for device companies.
Delivered through Apex's expert network: submission-grade regulatory and quality specialists for both agencies. Mark advises on the commercial side of the interface — keeping regulatory work aligned with your launch timeline rather than working against it.
Coverage determines commercial success. We build the economic evidence and payer strategy that turns regulatory clearance into actual revenue.
Building the commercial engine — high-performing teams structured for medtech selling environments — and securing the non-dilutive funding that extends your runway.